Bigway Medical Raises CNY 30M Series B to Scale Ophthalmic AI Diagnostics

Bigway Medical Closes CNY 30 Million Series B

Bigway Medical (比格威医疗), legally Suzhou Big Vision Medical Technology, has raised a CNY 30 million Series B round. The funding date is October 12, 2026, and the round was led by Ji'an Lanwan Venture Capital (吉安蓝湾创业投资), with participation from Jiangxi Modern Equity Investment (江西现代股权投资).

What the Company Does

Founded in 2015 and headquartered in Suzhou, Bigway Medical develops AI-assisted eye-disease diagnosis. Its offering combines intelligent imaging hardware, diagnostic software and a cloud data management platform.

• Hardware and software stack: The company builds imaging devices alongside the diagnostic software that interprets their output.
• Cloud data management: A cloud platform supports data handling across its installed base.
• Regulatory milestone: Its MIAS-3000 OCT analysis software was the first medical OCT AI system to receive China NMPA Class III registration, in October 2025.

Commercial Footprint

Bigway Medical's devices and software are used in more than 1,000 medical institutions across China. Since 2024, the company has expanded into Europe, the Americas, Asia and Africa, extending its reach beyond its domestic market.

Why the Round Matters for Acquirers

The Series B gives Bigway Medical fresh capital at a stage when ophthalmic AI is moving from pilot deployments toward regulated, reimbursable clinical use. Several elements of the profile are relevant to strategic buyers:

• Regulatory position: A Class III NMPA registration for an OCT AI system is a meaningful barrier to entry in the Chinese market and a signal of clinical validation.
• Installed base: More than 1,000 medical institutions provide a distribution footprint that would be costly to replicate.
• International expansion: Activity across Europe, the Americas, Asia and Africa since 2024 suggests the company is testing demand outside China, where regulatory pathways differ by jurisdiction.
• Integrated model: Combining imaging hardware, diagnostic software and cloud data management gives the company control over the full data path from capture to analysis.

Round Details

• Company: Bigway Medical (比格威医疗) / Suzhou Big Vision Medical Technology
• Round: Series B
• Amount: CNY 30 million
• Date: October 12, 2026
• Lead investor: Ji'an Lanwan Venture Capital (吉安蓝湾创业投资)
• Additional investor: Jiangxi Modern Equity Investment (江西现代股权投资)
• Headquarters: Suzhou, China
• Founded: 2015

What to Watch

For acquisition-oriented observers, the key questions are how quickly the company converts its Chinese installed base into recurring software and cloud revenue, and whether its international expansion produces regulatory clearances in target markets. The Series B capital is likely to be directed at commercial scaling, but the company has not disclosed specific use-of-proceeds details.

Bigway Medical sits at the intersection of medical imaging hardware and regulated clinical AI, a combination that tends to attract strategic interest from device manufacturers and healthcare data platforms seeking validated diagnostic assets.